-
1
-
-
33646413672
-
The global health burden of infection-associated cancers in the year 2002
-
Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118: 3030.
-
(2006)
Int J Cancer
, vol.118
, pp. 3030
-
-
Parkin, D.M.1
-
2
-
-
0030577120
-
Papillomavirus infections-a major cause of human cancers
-
zur Hausen H. Papillomavirus infections-a major cause of human cancers. Biochim Biophys Acta 1996; 1288:F55.
-
(1996)
Biochim Biophys Acta
, vol.1288
-
-
zur Hausen, H.1
-
3
-
-
0032840918
-
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide
-
Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12.
-
(1999)
J Pathol
, vol.189
, pp. 12
-
-
Walboomers, J.M.1
Jacobs, M.V.2
Manos, M.M.3
-
4
-
-
34547912100
-
Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: A randomized trial
-
Hildesheim A, Herrero R, Wacholder S, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007; 298: 743.
-
(2007)
JAMA
, vol.298
, pp. 743
-
-
Hildesheim, A.1
Herrero, R.2
Wacholder, S.3
-
5
-
-
20944448032
-
-
Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 271.
-
Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 271.
-
-
-
-
6
-
-
33646058566
-
Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial
-
Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367:1247.
-
(2006)
Lancet
, vol.367
, pp. 1247
-
-
Harper, D.M.1
Franco, E.L.2
Wheeler, C.M.3
-
7
-
-
0033561333
-
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer
-
Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999; 340:1144.
-
(1999)
N Engl J Med
, vol.340
, pp. 1144
-
-
Rose, P.G.1
Bundy, B.N.2
Watkins, E.B.3
-
8
-
-
0033561204
-
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer
-
Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999; 340: 1137.
-
(1999)
N Engl J Med
, vol.340
, pp. 1137
-
-
Morris, M.1
Eifel, P.J.2
Lu, J.3
-
9
-
-
0033561259
-
Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma
-
Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999; 340:1154.
-
(1999)
N Engl J Med
, vol.340
, pp. 1154
-
-
Keys, H.M.1
Bundy, B.N.2
Stehman, F.B.3
-
10
-
-
0033993937
-
Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix
-
Peters WA 3rd, Liu PY, Barrett RJ 2nd, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000; 18: 1606.
-
(2000)
J Clin Oncol
, vol.18
, pp. 1606
-
-
Peters 3rd, W.A.1
Liu, P.Y.2
Barrett 2nd, R.J.3
-
11
-
-
0032895783
-
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: A Gynecologic Oncology Group and Southwest Oncology Group study
-
Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999; 17: 1339.
-
(1999)
J Clin Oncol
, vol.17
, pp. 1339
-
-
Whitney, C.W.1
Sause, W.2
Bundy, B.N.3
-
14
-
-
0033829093
-
Association of human papillomavirus infection with carcinoma of the cervix uteri and its precursor lesions: Theoretical and practical implications
-
Milde-Langosch K, Riethdorf S, Loning T. Association of human papillomavirus infection with carcinoma of the cervix uteri and its precursor lesions: theoretical and practical implications. Virchows Arch 2000; 437: 227.
-
(2000)
Virchows Arch
, vol.437
, pp. 227
-
-
Milde-Langosch, K.1
Riethdorf, S.2
Loning, T.3
-
15
-
-
0036849734
-
Human papillomavirus immortalization and transformation functions
-
Munger K, Howley PM. Human papillomavirus immortalization and transformation functions. Virus Res 2002; 89: 213.
-
(2002)
Virus Res
, vol.89
, pp. 213
-
-
Munger, K.1
Howley, P.M.2
-
16
-
-
0037435011
-
Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway
-
Wei LH, Kuo ML, Chen CA, et al. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene 2003; 22: 1517.
-
(2003)
Oncogene
, vol.22
, pp. 1517
-
-
Wei, L.H.1
Kuo, M.L.2
Chen, C.A.3
-
17
-
-
0025909780
-
Oncogene expression in cervical intraepithelial neoplasia and invasive cancer of cervix
-
Pinion SB, Kennedy JH, Miller RW, MacLean AB. Oncogene expression in cervical intraepithelial neoplasia and invasive cancer of cervix. Lancet 1991; 337: 819.
-
(1991)
Lancet
, vol.337
, pp. 819
-
-
Pinion, S.B.1
Kennedy, J.H.2
Miller, R.W.3
MacLean, A.B.4
-
18
-
-
0033954247
-
Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha
-
Ravi R, Mookerjee B, Bhujwalla ZM, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 2000; 14: 34.
-
(2000)
Genes Dev
, vol.14
, pp. 34
-
-
Ravi, R.1
Mookerjee, B.2
Bhujwalla, Z.M.3
-
19
-
-
1542319129
-
Cancer without disease
-
Folkman J, Kalluri R. Cancer without disease. Nature 2004; 427: 787.
-
(2004)
Nature
, vol.427
, pp. 787
-
-
Folkman, J.1
Kalluri, R.2
-
20
-
-
0035505036
-
The human papillomavirus (HPV) 16 E6 oncoprotein leads to an increase in gene expression of the angiogenic switch molecule FGF-BP in non-immortalized human keratinocytes
-
Stoppler H, Malerczyk C, Block K, Aigner A, Czubayko F. The human papillomavirus (HPV) 16 E6 oncoprotein leads to an increase in gene expression of the angiogenic switch molecule FGF-BP in non-immortalized human keratinocytes. Oncogene 2001; 20: 7430.
-
(2001)
Oncogene
, vol.20
, pp. 7430
-
-
Stoppler, H.1
Malerczyk, C.2
Block, K.3
Aigner, A.4
Czubayko, F.5
-
21
-
-
0034953328
-
-
Tjalma WA, Weyler JJ, Bogers JJ, et al. The importance of biological factors (bcl-2, bax, p53, PCNA, MI, HPV and angiogenesis) in invasive cervical cancer. Eur J Obstet Gynecol Reprod Biol 2001; 97: 223.
-
Tjalma WA, Weyler JJ, Bogers JJ, et al. The importance of biological factors (bcl-2, bax, p53, PCNA, MI, HPV and angiogenesis) in invasive cervical cancer. Eur J Obstet Gynecol Reprod Biol 2001; 97: 223.
-
-
-
-
22
-
-
2442505482
-
Expression of human papillomavirus type 16 E6 and E7 oncoproteins in primary foreskin keratinocytes is sufficient to alter the expression of angiogenic factors
-
Toussaint-Smith E, Donner DB, Roman A. Expression of human papillomavirus type 16 E6 and E7 oncoproteins in primary foreskin keratinocytes is sufficient to alter the expression of angiogenic factors. Oncogene 2004; 23: 2988.
-
(2004)
Oncogene
, vol.23
, pp. 2988
-
-
Toussaint-Smith, E.1
Donner, D.B.2
Roman, A.3
-
23
-
-
0034649199
-
Angiogenesis modulators expression in culture cell lines positives for HPV-16 oncoproteins
-
Bequet-Romero M, Lopez-Ocejo O. Angiogenesis modulators expression in culture cell lines positives for HPV-16 oncoproteins. Biochem Biophys Res Commun 2000; 277: 55.
-
(2000)
Biochem Biophys Res Commun
, vol.277
, pp. 55
-
-
Bequet-Romero, M.1
Lopez-Ocejo, O.2
-
24
-
-
0034703613
-
Impaired angiogenic balance and suppression of tumorigenicity in HeLa cells chronically exposed to interferon-alpha
-
Lopez-Ocejo O, Perea SE, Bequet-Romero M, Arana MJ, Lopez Saura P. Impaired angiogenic balance and suppression of tumorigenicity in HeLa cells chronically exposed to interferon-alpha. Biochem Biophys Res Commun 2000; 277: 410.
-
(2000)
Biochem Biophys Res Commun
, vol.277
, pp. 410
-
-
Lopez-Ocejo, O.1
Perea, S.E.2
Bequet-Romero, M.3
Arana, M.J.4
Lopez Saura, P.5
-
25
-
-
3442888565
-
Thrombospondin-1 acts as a fence to inhibit angiogenesis that occurs during cervical carcinogenesis
-
Wu MP, Tzeng CC, Wu LW, Huang KF, Chou CY. Thrombospondin-1 acts as a fence to inhibit angiogenesis that occurs during cervical carcinogenesis. Cancer J 2004; 10: 27.
-
(2004)
Cancer J
, vol.10
, pp. 27
-
-
Wu, M.P.1
Tzeng, C.C.2
Wu, L.W.3
Huang, K.F.4
Chou, C.Y.5
-
26
-
-
0030989017
-
Cross-species comparison of angiogenesis during the premalignant stages of squamous carcinogenesis in the human cervix and K14-HPV16 transgenic mice
-
Smith-McCune K, Zhu YH, Hanahan D, Arbeit J. Cross-species comparison of angiogenesis during the premalignant stages of squamous carcinogenesis in the human cervix and K14-HPV16 transgenic mice. Cancer Res 1997; 57: 1294.
-
(1997)
Cancer Res
, vol.57
, pp. 1294
-
-
Smith-McCune, K.1
Zhu, Y.H.2
Hanahan, D.3
Arbeit, J.4
-
28
-
-
0004011756
-
Vascular endothelial growth factor is implicated in early invasion in cervical cancer
-
Kodama J, Seki N, Tokumo K, et al. Vascular endothelial growth factor is implicated in early invasion in cervical cancer. Eur J Cancer 1999; 35: 485.
-
(1999)
Eur J Cancer
, vol.35
, pp. 485
-
-
Kodama, J.1
Seki, N.2
Tokumo, K.3
-
29
-
-
0037139421
-
Correlation between vascular endothelial growth factor-C expression and invasion phenotype in cervical carcinomas
-
Ueda M, Terai Y, Yamashita Y, et al. Correlation between vascular endothelial growth factor-C expression and invasion phenotype in cervical carcinomas. Int J Cancer 2002; 98: 335.
-
(2002)
Int J Cancer
, vol.98
, pp. 335
-
-
Ueda, M.1
Terai, Y.2
Yamashita, Y.3
-
30
-
-
0033899157
-
Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix
-
Loncaster JA, Cooper RA, Logue JP, et al. Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix. Br J Cancer 2000; 83: 620.
-
(2000)
Br J Cancer
, vol.83
, pp. 620
-
-
Loncaster, J.A.1
Cooper, R.A.2
Logue, J.P.3
-
31
-
-
21344443061
-
Mosaic tumor vessels: Cellular basis and ultrastructure of focal regions lacking endothelial cell markers
-
di Tomaso E, Capen D, Haskell A, et al. Mosaic tumor vessels: cellular basis and ultrastructure of focal regions lacking endothelial cell markers. Cancer Res 2005; 65: 5740.
-
(2005)
Cancer Res
, vol.65
, pp. 5740
-
-
di Tomaso, E.1
Capen, D.2
Haskell, A.3
-
32
-
-
11844254414
-
Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
-
Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307:58.
-
(2005)
Science
, vol.307
, pp. 58
-
-
Jain, R.K.1
-
33
-
-
0038172576
-
Cancer: Out of air is not out of action
-
Bottaro DP, Liotta LA. Cancer: Out of air is not out of action. Nature 2003; 423: 593.
-
(2003)
Nature
, vol.423
, pp. 593
-
-
Bottaro, D.P.1
Liotta, L.A.2
-
34
-
-
3142631966
-
The human tumor microenvironment: Invasive (needle) measurement of oxygen and interstitial fluid pressure
-
Milosevic M, Fyles A, Hedley D, Hill R. The human tumor microenvironment: invasive (needle) measurement of oxygen and interstitial fluid pressure. Semin Radiat Oncol 2004; 14: 249.
-
(2004)
Semin Radiat Oncol
, vol.14
, pp. 249
-
-
Milosevic, M.1
Fyles, A.2
Hedley, D.3
Hill, R.4
-
35
-
-
0035417889
-
Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumor oxygen measurements
-
Milosevic M, Fyles A, Hedley D, et al. Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumor oxygen measurements. Cancer Res 2001; 61: 6400.
-
(2001)
Cancer Res
, vol.61
, pp. 6400
-
-
Milosevic, M.1
Fyles, A.2
Hedley, D.3
-
36
-
-
0037288375
-
A model for temporal heterogeneities of tumor blood flow
-
Mollica F, Jain RK, Netti PA. A model for temporal heterogeneities of tumor blood flow. Microvasc Res 2003; 65: 56.
-
(2003)
Microvasc Res
, vol.65
, pp. 56
-
-
Mollica, F.1
Jain, R.K.2
Netti, P.A.3
-
37
-
-
10644283057
-
Hypoxia and anemia: Factors in decreased sensitivity to radiation therapy and chemotherapy?
-
Harrison L, Blackwell K. Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist 2004; 9(Suppl 5): 31.
-
(2004)
Oncologist
, vol.9
, Issue.SUPPL. 5
, pp. 31
-
-
Harrison, L.1
Blackwell, K.2
-
38
-
-
0018760476
-
Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation
-
Brown JM. Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation. Br J Radiol 1979; 52: 650.
-
(1979)
Br J Radiol
, vol.52
, pp. 650
-
-
Brown, J.M.1
-
39
-
-
0034016439
-
Disease control of uterine cervical cancer: Relationships to tumor oxygen tension, vascular density, cell density, and frequency of mitosis and apoptosis measured before treatment and during radiotherapy
-
Lyng H, Sundfor K, Trope C, Rofstad EK. Disease control of uterine cervical cancer: relationships to tumor oxygen tension, vascular density, cell density, and frequency of mitosis and apoptosis measured before treatment and during radiotherapy. Clin Cancer Res 2000; 6:1104.
-
(2000)
Clin Cancer Res
, vol.6
, pp. 1104
-
-
Lyng, H.1
Sundfor, K.2
Trope, C.3
Rofstad, E.K.4
-
40
-
-
0036467638
-
Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer
-
Fyles A, Milosevic M, Hedley D, et al. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol 2002; 20: 680.
-
(2002)
J Clin Oncol
, vol.20
, pp. 680
-
-
Fyles, A.1
Milosevic, M.2
Hedley, D.3
-
41
-
-
0037430244
-
GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: Relationship to pimonidazole binding
-
Airley RE, Loncaster J, Raleigh JA, et al. GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding. Int J Cancer 2003; 104: 85.
-
(2003)
Int J Cancer
, vol.104
, pp. 85
-
-
Airley, R.E.1
Loncaster, J.2
Raleigh, J.A.3
-
42
-
-
0037847453
-
Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas
-
Nordsmark M, Loncaster J, Aquino-Parsons C, et al. Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas. Radiother Oncol 2003; 67: 35.
-
(2003)
Radiother Oncol
, vol.67
, pp. 35
-
-
Nordsmark, M.1
Loncaster, J.2
Aquino-Parsons, C.3
-
43
-
-
0038300418
-
Significant correlation of hypoxia-inducible factor-1alpha with treatment outcome in cervical cancer treated with radical radiotherapy
-
Burri P, Djonov V, Aebersold DM, et al. Significant correlation of hypoxia-inducible factor-1alpha with treatment outcome in cervical cancer treated with radical radiotherapy, Int J Radiat Oncol Biol Phys 2003; 56: 494.
-
(2003)
Int J Radiat Oncol Biol Phys
, vol.56
, pp. 494
-
-
Burri, P.1
Djonov, V.2
Aebersold, D.M.3
-
44
-
-
0029775242
-
Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix
-
Hockel M, Schlenger K, Aral B, et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996; 56: 4509.
-
(1996)
Cancer Res
, vol.56
, pp. 4509
-
-
Hockel, M.1
Schlenger, K.2
Aral, B.3
-
45
-
-
0037480606
-
Hypoxie cervical cancers with low apoptotic index are highly aggressive
-
Hockel M, Schlenger K, Hockel S, Vaupel P. Hypoxie cervical cancers with low apoptotic index are highly aggressive. Cancer Res 1999; 59: 4525.
-
(1999)
Cancer Res
, vol.59
, pp. 4525
-
-
Hockel, M.1
Schlenger, K.2
Hockel, S.3
Vaupel, P.4
-
46
-
-
33748150486
-
Long-term performance of interstial fluid pressure and hypoxia as prognostic factors in cervix cancer
-
Fyles A, Milosevic M, Pintilie M, et al. Long-term performance of interstial fluid pressure and hypoxia as prognostic factors in cervix cancer. Radiother Oncol 2006; 80: 132.
-
(2006)
Radiother Oncol
, vol.80
, pp. 132
-
-
Fyles, A.1
Milosevic, M.2
Pintilie, M.3
-
47
-
-
0142166332
-
Targeting HIF-1 for cancer therapy
-
Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721.
-
(2003)
Nat Rev Cancer
, vol.3
, pp. 721
-
-
Semenza, G.L.1
-
48
-
-
2342611976
-
Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: Role of reoxygenation, free radicals, and stress granules
-
Moeller BJ, Cao Y, Li CY, Dewhirst MW. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 2004; 5: 429.
-
(2004)
Cancer Cell
, vol.5
, pp. 429
-
-
Moeller, B.J.1
Cao, Y.2
Li, C.Y.3
Dewhirst, M.W.4
-
49
-
-
34347389461
-
Tumor hypoxia, DNA repair and prostate cancer progression: New targets and new therapies
-
Chan N, Milosevic M, Bristow RG. Tumor hypoxia, DNA repair and prostate cancer progression: new targets and new therapies. Future Oncol 2007; 3: 329.
-
(2007)
Future Oncol
, vol.3
, pp. 329
-
-
Chan, N.1
Milosevic, M.2
Bristow, R.G.3
-
50
-
-
34249010891
-
Overexpression of human papillomavirus type 16 oncoproteins enhances hypoxia-inducible factor 1 alpha protein accumulation and vascular endothelial growth factor expression in human cervical carcinoma cells
-
Tang X, Zhang Q, Nishitani J, et al. Overexpression of human papillomavirus type 16 oncoproteins enhances hypoxia-inducible factor 1 alpha protein accumulation and vascular endothelial growth factor expression in human cervical carcinoma cells. Clin Cancer Res 2007; 13: 2568.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 2568
-
-
Tang, X.1
Zhang, Q.2
Nishitani, J.3
-
51
-
-
33746899015
-
Akt1 activation can augment hypoxia-inducible factor-1alpha expression by increasing protein translation through a mammalian target of rapamycin-independent pathway
-
Pore N, Jiang Z, Shu HK, et al. Akt1 activation can augment hypoxia-inducible factor-1alpha expression by increasing protein translation through a mammalian target of rapamycin-independent pathway. Mol Cancer Res 2006; 4: 471.
-
(2006)
Mol Cancer Res
, vol.4
, pp. 471
-
-
Pore, N.1
Jiang, Z.2
Shu, H.K.3
-
52
-
-
0037205048
-
The phosphoinositide 3-kinase pathway
-
Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296: 1655.
-
(2002)
Science
, vol.296
, pp. 1655
-
-
Cantley, L.C.1
-
53
-
-
2942696404
-
Epigenetic and genetic alternation of PTEN in cervical neoplasm
-
Cheung TH, Lo KW, Yim SF, et al. Epigenetic and genetic alternation of PTEN in cervical neoplasm. Gynecol Oncol 2004; 93: 621.
-
(2004)
Gynecol Oncol
, vol.93
, pp. 621
-
-
Cheung, T.H.1
Lo, K.W.2
Yim, S.F.3
-
54
-
-
33645226001
-
Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: Frequent PIK3CA amplification and AKT phosphorylation
-
Bertelsen BI, Steine SJ, Sandvei R, Molven A, Laerum OD. Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: frequent PIK3CA amplification and AKT phosphorylation. Int J Cancer 2006; 118:1877.
-
(2006)
Int J Cancer
, vol.118
, pp. 1877
-
-
Bertelsen, B.I.1
Steine, S.J.2
Sandvei, R.3
Molven, A.4
Laerum, O.D.5
-
55
-
-
0034050050
-
Loss of PTEN facilitates HIF-1-mediated gene expression
-
Zundel W, Schindler C, Haas-Kogan D, et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 2000; 14: 391.
-
(2000)
Genes Dev
, vol.14
, pp. 391
-
-
Zundel, W.1
Schindler, C.2
Haas-Kogan, D.3
-
56
-
-
31544444486
-
Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cervical cancer cell lines
-
Lee CM, Fuhrman CB, Planelles V, et al. Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cervical cancer cell lines. Clin Cancer Res 2006; 12: 250.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 250
-
-
Lee, C.M.1
Fuhrman, C.B.2
Planelles, V.3
-
57
-
-
0042031047
-
A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets
-
Arsham AM, Howell JJ, Simon MC. A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J Biol Chem 2003; 278: 29655.
-
(2003)
J Biol Chem
, vol.278
, pp. 29655
-
-
Arsham, A.M.1
Howell, J.J.2
Simon, M.C.3
-
58
-
-
0036789574
-
Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin
-
Hudson CC, Liu M, Chiang GG, et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002; 22: 7004.
-
(2002)
Mol Cell Biol
, vol.22
, pp. 7004
-
-
Hudson, C.C.1
Liu, M.2
Chiang, G.G.3
-
59
-
-
0041920901
-
TSC2 regulates VEGP through mTOR-dependent and -independent pathways
-
Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG Jr. TSC2 regulates VEGP through mTOR-dependent and -independent pathways. Cancer Cell 2003; 4: 147.
-
(2003)
Cancer Cell
, vol.4
, pp. 147
-
-
Brugarolas, J.B.1
Vazquez, F.2
Reddy, A.3
Sellers, W.R.4
Kaelin Jr, W.G.5
-
60
-
-
0030980345
-
The coupling of alpha6beta4 integrin to Ras-MAP kinase pathways mediated by Shc controls keratinocyte proliferation
-
Mainiero F, Murgia C, Wary KK, et al. The coupling of alpha6beta4 integrin to Ras-MAP kinase pathways mediated by Shc controls keratinocyte proliferation. EMBO J 1997; 16: 2365.
-
(1997)
EMBO J
, vol.16
, pp. 2365
-
-
Mainiero, F.1
Murgia, C.2
Wary, K.K.3
-
61
-
-
0032538449
-
Distinct mechanisms mediate the initial and sustained phases of integrin-mediated activation of the Raf/MEK/ mitogen-activated protein kinase cascade
-
Howe AK, Juliano RL. Distinct mechanisms mediate the initial and sustained phases of integrin-mediated activation of the Raf/MEK/ mitogen-activated protein kinase cascade. J Biol Chem 1998; 273: 27268.
-
(1998)
J Biol Chem
, vol.273
, pp. 27268
-
-
Howe, A.K.1
Juliano, R.L.2
-
63
-
-
12244298243
-
New and active role of the interstitium in control of interstitial fluid pressure: Potential therapeutic consequences
-
Wiig H, Rubin K, Reed RK. New and active role of the interstitium in control of interstitial fluid pressure: potential therapeutic consequences. Acta Anaesthesiol Scand 2003; 47: 111.
-
(2003)
Acta Anaesthesiol Scand
, vol.47
, pp. 111
-
-
Wiig, H.1
Rubin, K.2
Reed, R.K.3
-
65
-
-
33847640529
-
Exploitable mechanisms for combining drugs with radiation: Concepts, achievements and future directions
-
Bentzen SM, Harari PM, Bernier J. Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions. Nat Clin Pract Oncol 2007; 4: 172.
-
(2007)
Nat Clin Pract Oncol
, vol.4
, pp. 172
-
-
Bentzen, S.M.1
Harari, P.M.2
Bernier, J.3
-
66
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
-
Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205.
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 205
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
-
67
-
-
37049017075
-
Cervix cancer regression measured using weekly MR imaging during fractionated radiotherapy: Radiobiologic modeling and correlation with tumor hypoxia
-
Lim KC, Fyles A, Dinniwell R, et al. Cervix cancer regression measured using weekly MR imaging during fractionated radiotherapy: radiobiologic modeling and correlation with tumor hypoxia. Int J Radiol Oncol Biol Phys 2008; 70(1): 126-33.
-
(2008)
Int J Radiol Oncol Biol Phys
, vol.70
, Issue.1
, pp. 126-133
-
-
Lim, K.C.1
Fyles, A.2
Dinniwell, R.3
-
68
-
-
33749316418
-
The epidermal growth factor receptor pathway: A model for targeted therapy
-
Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 2006; 12: 5268.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 5268
-
-
Scaltriti, M.1
Baselga, J.2
-
69
-
-
33746485766
-
Epidermal growth factor receptor targeting in cancer
-
Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006; 33: 369.
-
(2006)
Semin Oncol
, vol.33
, pp. 369
-
-
Mendelsohn, J.1
Baselga, J.2
-
70
-
-
0000091450
-
The effect of ionizing radiation on signal transduction: Antibodies to EGF receptor sensitize A431 cells to radiation
-
Balaban N, Moni J, Shannon M, et al. The effect of ionizing radiation on signal transduction: antibodies to EGF receptor sensitize A431 cells to radiation. Biochim Biophys Acta 1996; 1314: 147.
-
(1996)
Biochim Biophys Acta
, vol.1314
, pp. 147
-
-
Balaban, N.1
Moni, J.2
Shannon, M.3
-
71
-
-
0030772168
-
Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation
-
Schmidt-Ullrich RK, Mikkelsen RB, Dent P, et al. Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 1997; 15: 1191.
-
(1997)
Oncogene
, vol.15
, pp. 1191
-
-
Schmidt-Ullrich, R.K.1
Mikkelsen, R.B.2
Dent, P.3
-
73
-
-
0032719534
-
Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas
-
Akimoto T, Hunter NR, Buchmiller L, et al. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 1999; 5: 2884.
-
(1999)
Clin Cancer Res
, vol.5
, pp. 2884
-
-
Akimoto, T.1
Hunter, N.R.2
Buchmiller, L.3
-
74
-
-
0033561522
-
Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck
-
Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999; 59: 1935.
-
(1999)
Cancer Res
, vol.59
, pp. 1935
-
-
Huang, S.M.1
Bock, J.M.2
Harari, P.M.3
-
75
-
-
17344382185
-
Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation
-
Saleh MN, Raisch KP, Stackhouse MA, et al. Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. Cancer Biother Radiopharm 1999; 14: 451.
-
(1999)
Cancer Biother Radiopharm
, vol.14
, pp. 451
-
-
Saleh, M.N.1
Raisch, K.P.2
Stackhouse, M.A.3
-
76
-
-
17144371349
-
Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva)
-
Chinnaiyan P, Huang S, Vallabhaneni G, et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 2005; 65: 3328.
-
(2005)
Cancer Res
, vol.65
, pp. 3328
-
-
Chinnaiyan, P.1
Huang, S.2
Vallabhaneni, G.3
-
77
-
-
0347928791
-
EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor
-
Solomon B, Hagekyriakou J, Trivett MK, et al. EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor. Int J Radiat Oncol Biol Phys 2003; 55: 713.
-
(2003)
Int J Radiat Oncol Biol Phys
, vol.55
, pp. 713
-
-
Solomon, B.1
Hagekyriakou, J.2
Trivett, M.K.3
-
78
-
-
0033966576
-
In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody
-
Milas L, Mason K, Hunter N, et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000; 6: 701.
-
(2000)
Clin Cancer Res
, vol.6
, pp. 701
-
-
Milas, L.1
Mason, K.2
Hunter, N.3
-
79
-
-
32144433159
-
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
-
Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567.
-
(2006)
N Engl J Med
, vol.354
, pp. 567
-
-
Bonner, J.A.1
Harari, P.M.2
Giralt, J.3
-
80
-
-
0034816985
-
Human papilloma virns (HPV)-E6/ E7 and epidermal growth factor receptor (EGF-R) protein levels in cervical cancer and cervical intraepithelial neoplasia (CIN)
-
Mathur SP, Mathur RS, Rust PF, Young RC. Human papilloma virns (HPV)-E6/ E7 and epidermal growth factor receptor (EGF-R) protein levels in cervical cancer and cervical intraepithelial neoplasia (CIN). Am J Reprod Immunol 2001; 46: 280.
-
(2001)
Am J Reprod Immunol
, vol.46
, pp. 280
-
-
Mathur, S.P.1
Mathur, R.S.2
Rust, P.F.3
Young, R.C.4
-
81
-
-
0038386695
-
Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy
-
Gaffney DK, Haslam D, Tsodikov A, et al. Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys 2003; 56: 922.
-
(2003)
Int J Radiat Oncol Biol Phys
, vol.56
, pp. 922
-
-
Gaffney, D.K.1
Haslam, D.2
Tsodikov, A.3
-
82
-
-
55849091554
-
Erlotinib, cisplatin and radiotherapy for patients with cervical cancer. A phase I trial
-
Abs
-
Rodrigues AN, Do Carmo CC, Viegas F, et al. Erlotinib, cisplatin and radiotherapy for patients with cervical cancer. A phase I trial. ASCO Annual Meeting Proceedings, J Clin Oncol 2007; Vol. 25, 18S, Abs 5592.
-
(2007)
ASCO Annual Meeting Proceedings, J Clin Oncol
, vol.25
, Issue.18 S
, pp. 5592
-
-
Rodrigues, A.N.1
Do Carmo, C.C.2
Viegas, F.3
-
83
-
-
0036236186
-
Celecoxib: A specific COX-2 inhibitor with anticancer properties
-
Koki AT, Masferrer JL. Celecoxib: a specific COX-2 inhibitor with anticancer properties. Cancer Control 2002; 9: 28.
-
(2002)
Cancer Control
, vol.9
, pp. 28
-
-
Koki, A.T.1
Masferrer, J.L.2
-
84
-
-
0037215435
-
High cyclooxygenase-2 expression is related with distant metastasis in cervical cancer treated with radiotherapy
-
Kim HJ, Wu HG, Park IA, Ha SW. High cyclooxygenase-2 expression is related with distant metastasis in cervical cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 2003; 55: 16.
-
(2003)
Int J Radiat Oncol Biol Phys
, vol.55
, pp. 16
-
-
Kim, H.J.1
Wu, H.G.2
Park, I.A.3
Ha, S.W.4
-
85
-
-
0035312493
-
Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy
-
Gaffney DK, Holden J, Davis M, et al. Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys 2001; 49: 1213.
-
(2001)
Int J Radiat Oncol Biol Phys
, vol.49
, pp. 1213
-
-
Gaffney, D.K.1
Holden, J.2
Davis, M.3
-
86
-
-
0034011262
-
High cyclooxygenase-2 expression in stage IB cervical cancer with lymph node metastasis or parametrial invasion
-
Ryu HS, Chang KH, Yang HW, et al. High cyclooxygenase-2 expression in stage IB cervical cancer with lymph node metastasis or parametrial invasion. Gynecol Oncol 2000; 76: 320.
-
(2000)
Gynecol Oncol
, vol.76
, pp. 320
-
-
Ryu, H.S.1
Chang, K.H.2
Yang, H.W.3
-
87
-
-
4344713687
-
Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-kappaB as a possible target
-
Kim SH, Song SH, Kim SG, et al. Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-kappaB as a possible target. J Cancer Res Clin Oncol 2004; 130: 551.
-
(2004)
J Cancer Res Clin Oncol
, vol.130
, pp. 551
-
-
Kim, S.H.1
Song, S.H.2
Kim, S.G.3
-
88
-
-
0942278941
-
Potentiation of tumor response to radiation or chemoradiation by selective cyclooxygenase-2 enzyme inhibitors
-
Nakata E, Mason KA, Hunter N, et al. Potentiation of tumor response to radiation or chemoradiation by selective cyclooxygenase-2 enzyme inhibitors. Int J Radiat Oncol Biol Phys 2004; 58: 369.
-
(2004)
Int J Radiat Oncol Biol Phys
, vol.58
, pp. 369
-
-
Nakata, E.1
Mason, K.A.2
Hunter, N.3
-
89
-
-
0036834430
-
In vitro enhancement of tumor cell radiosensitivity by a selective inhibitor of cyclooxygenase-2 enzyme: Mechanistic considerations
-
Raju U, Nakata E, Yang P, et al. In vitro enhancement of tumor cell radiosensitivity by a selective inhibitor of cyclooxygenase-2 enzyme: mechanistic considerations. Int J Radiat Oncol Biol Phys 2002; 54: 886.
-
(2002)
Int J Radiat Oncol Biol Phys
, vol.54
, pp. 886
-
-
Raju, U.1
Nakata, E.2
Yang, P.3
-
90
-
-
0034161878
-
Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors
-
Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60: 1306.
-
(2000)
Cancer Res
, vol.60
, pp. 1306
-
-
Masferrer, J.L.1
Leahy, K.M.2
Koki, A.T.3
-
91
-
-
33845682489
-
A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: Primary endpoint analysis of RTOG 0128
-
Gaffney DK, Winter K, Dicker AP, et al. A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128. Int J Radiat Oncol Biol Phys 2007; 67: 104.
-
(2007)
Int J Radiat Oncol Biol Phys
, vol.67
, pp. 104
-
-
Gaffney, D.K.1
Winter, K.2
Dicker, A.P.3
-
92
-
-
34547842086
-
Efficacy and patterns of failure for locally advanced cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128
-
Gaffney DK, Winter K, Dicker AP, et al. Efficacy and patterns of failure for locally advanced cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128. Int J Radiat Oncol Biol Phys 2007; 69(1):111-7.
-
(2007)
Int J Radiat Oncol Biol Phys
, vol.69
, Issue.1
, pp. 111-117
-
-
Gaffney, D.K.1
Winter, K.2
Dicker, A.P.3
-
93
-
-
33845627724
-
A prospective phase I-II trial of the cyclooxygenase-2 inhibitor celecoxib in patients with carcinoma of the cervix with biomarker assessment of the tumor microenvironment
-
Herrera FG, Chan P, Doll C, et al. A prospective phase I-II trial of the cyclooxygenase-2 inhibitor celecoxib in patients with carcinoma of the cervix with biomarker assessment of the tumor microenvironment. Int J Radiat Oncol Biol Phys 2007; 67: 97.
-
(2007)
Int J Radiat Oncol Biol Phys
, vol.67
, pp. 97
-
-
Herrera, F.G.1
Chan, P.2
Doll, C.3
-
94
-
-
0034306974
-
Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions
-
Lee CG, Heijn M, di Tomaso E, et al. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000; 60: 5565.
-
(2000)
Cancer Res
, vol.60
, pp. 5565
-
-
Lee, C.G.1
Heijn, M.2
di Tomaso, E.3
-
95
-
-
11144354392
-
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
-
Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10: 145.
-
(2004)
Nat Med
, vol.10
, pp. 145
-
-
Willett, C.G.1
Boucher, Y.2
di Tomaso, E.3
-
96
-
-
33750360895
-
Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: Theory and clinical practice
-
Willett CG, Kozin SV, Duda DG, et al. Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice. Semin Oncol 2006; 33: S35.
-
(2006)
Semin Oncol
, vol.33
-
-
Willett, C.G.1
Kozin, S.V.2
Duda, D.G.3
-
97
-
-
0347615101
-
Dynamic contrast-enhanced magnetic resonance imaging an a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: Results from two phase I studies
-
Morgan B, Thomas AL, Drevs J, et al. Dynamic contrast-enhanced magnetic resonance imaging an a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003; 21: 3955.
-
(2003)
J Clin Oncol
, vol.21
, pp. 3955
-
-
Morgan, B.1
Thomas, A.L.2
Drevs, J.3
-
98
-
-
33744466541
-
Antiangiogenic therapy: A universal chemosensitization strategy for cancer?
-
Kerbel RS. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 2006; 312:1171.
-
(2006)
Science
, vol.312
, pp. 1171
-
-
Kerbel, R.S.1
-
99
-
-
18744393143
-
Prediction of radiotherapy outcome using dynamic contrast enhanced MRI of carcinoma of the cervix
-
Loncaster JA, Carrington BM, Sykes JR, et al. Prediction of radiotherapy outcome using dynamic contrast enhanced MRI of carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2002; 54: 759.
-
(2002)
Int J Radiat Oncol Biol Phys
, vol.54
, pp. 759
-
-
Loncaster, J.A.1
Carrington, B.M.2
Sykes, J.R.3
-
101
-
-
33845645028
-
Dynamic contrast-enhanced MRI as a predictor of tumour response to radiotherapy
-
Zahra MA, Hollingsworth KG, Sala E, Lomas DJ, Tan LT. Dynamic contrast-enhanced MRI as a predictor of tumour response to radiotherapy. Lancet Oncol 2007; 8: 63.
-
(2007)
Lancet Oncol
, vol.8
, pp. 63
-
-
Zahra, M.A.1
Hollingsworth, K.G.2
Sala, E.3
Lomas, D.J.4
Tan, L.T.5
-
102
-
-
33846257299
-
Correlations between dynamic contrast-enhanced magnetic resonance imaging-derived measures of tumor microvasculature and interstitial fluid pressure in patients with cervical cancer
-
Haider MA, Sitartchouk I, Roberts TP, et al. Correlations between dynamic contrast-enhanced magnetic resonance imaging-derived measures of tumor microvasculature and interstitial fluid pressure in patients with cervical cancer. J Magn Reson Imaging 2007; 25: 153.
-
(2007)
J Magn Reson Imaging
, vol.25
, pp. 153
-
-
Haider, M.A.1
Sitartchouk, I.2
Roberts, T.P.3
-
103
-
-
27144458749
-
Comparison of late toxicity between continuous low-dose-rate and pulsed-dose-rate brachytherapy in cervical cancer patients
-
Bachtiary B, Dewitt A, Pintilie M, et al. Comparison of late toxicity between continuous low-dose-rate and pulsed-dose-rate brachytherapy in cervical cancer patients. Int J Radiat Oncol Biol Phys 2005; 63: 1077.
-
(2005)
Int J Radiat Oncol Biol Phys
, vol.63
, pp. 1077
-
-
Bachtiary, B.1
Dewitt, A.2
Pintilie, M.3
-
104
-
-
0035297541
-
Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors
-
Pietras K, Ostman A, Sjoquist M, et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001; 61: 2929.
-
(2001)
Cancer Res
, vol.61
, pp. 2929
-
-
Pietras, K.1
Ostman, A.2
Sjoquist, M.3
-
105
-
-
0038476608
-
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors
-
Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003; 111: 1287.
-
(2003)
J Clin Invest
, vol.111
, pp. 1287
-
-
Bergers, G.1
Song, S.2
Meyer-Morse, N.3
Bergsland, E.4
Hanahan, D.5
-
106
-
-
3543002277
-
VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis
-
Dong J, Grunstein J, Tejada M, et al. VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J 2004; 23: 2800.
-
(2004)
EMBO J
, vol.23
, pp. 2800
-
-
Dong, J.1
Grunstein, J.2
Tejada, M.3
-
107
-
-
0036790060
-
Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy
-
Pietras K, Rubin K, Sjoblom T, et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002; 62: 5476.
-
(2002)
Cancer Res
, vol.62
, pp. 5476
-
-
Pietras, K.1
Rubin, K.2
Sjoblom, T.3
-
109
-
-
4944249117
-
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
-
Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099.
-
(2004)
Cancer Res
, vol.64
, pp. 7099
-
-
Wilhelm, S.M.1
Carter, C.2
Tang, L.3
-
110
-
-
23044510046
-
Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors
-
Clark JW, Eder JP, Ryan D, Lathia C, Lenz HJ. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005; 11: 5472.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 5472
-
-
Clark, J.W.1
Eder, J.P.2
Ryan, D.3
Lathia, C.4
Lenz, H.J.5
-
111
-
-
33749238553
-
Discovery and development of sorafenib: A multikinase inhibitor for treating cancer
-
Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006; 5: 835.
-
(2006)
Nat Rev Drug Discov
, vol.5
, pp. 835
-
-
Wilhelm, S.1
Carter, C.2
Lynch, M.3
-
112
-
-
33845594648
-
A comparison of quality of life and symptoms in kidney cancer patients receiving sorafenib versus placebo
-
Dhanda R, GK, Song J, et al. A comparison of quality of life and symptoms in kidney cancer patients receiving sorafenib versus placebo. Proc Am Soc Clin Oncol 2006; Vol 24, No. 18S, 4534.
-
(2006)
Proc Am Soc Clin Oncol
, vol.24
, Issue.18 S
, pp. 4534
-
-
Dhanda, R.G.1
Song, J.2
-
113
-
-
34548315347
-
Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma. Survival and biomarker analysis
-
Eisen T, BR, Staehler M, et al. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma. Survival and biomarker analysis. Proc Am Soc Clin Oncol 2007; Vol 25, No. 18S, 5023.
-
(2007)
Proc Am Soc Clin Oncol
, vol.25
, Issue.18 S
, pp. 5023
-
-
Eisen, T.B.1
Staehler, M.2
-
114
-
-
34548720158
-
Sorafenib improves survival in advanced Hepatocellular Carcinoma (HCC): Results of a Phase III randomized placebo-controlled trial (SHARP trial)
-
25, No. 18S
-
Llovet J, Ricci S, Mazzaferro V, et al. Sorafenib improves survival in advanced Hepatocellular Carcinoma (HCC): Results of a Phase III randomized placebo-controlled trial (SHARP trial). Proc Am Soc Clin Oncol Part I. 2007; Vol 25, No. 18S.
-
(2007)
Proc Am Soc Clin Oncol
, Issue.PART I
-
-
Llovet, J.1
Ricci, S.2
Mazzaferro, V.3
-
115
-
-
3543083957
-
Association of hemoglobin level with survival in cervical carcinoma patients treated with concurrent cisplatin and radiotherapy: A Gynecologic Oncology Group Study
-
Winter WE 3rd, Maxwell GL, Tian C, et al. Association of hemoglobin level with survival in cervical carcinoma patients treated with concurrent cisplatin and radiotherapy: a Gynecologic Oncology Group Study. Gynecol Oncol 2004; 94: 495.
-
(2004)
Gynecol Oncol
, vol.94
, pp. 495
-
-
Winter 3rd, W.E.1
Maxwell, G.L.2
Tian, C.3
-
116
-
-
0017977265
-
Definitive evidence for hypoxic cells influencing cure in cancer therapy
-
Bush RS, Jenkin RD, Allt WE, et al. Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer Suppl 1978; 37: 302.
-
(1978)
Br J Cancer Suppl
, vol.37
, pp. 302
-
-
Bush, R.S.1
Jenkin, R.D.2
Allt, W.E.3
-
117
-
-
0041976976
-
Breast cancer trial with erythropoietin terminated unexpectedly
-
Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003; 4: 459.
-
(2003)
Lancet Oncol
, vol.4
, pp. 459
-
-
Leyland-Jones, B.1
-
118
-
-
0142186283
-
Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial
-
Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003; 362: 1255.
-
(2003)
Lancet
, vol.362
, pp. 1255
-
-
Henke, M.1
Laszig, R.2
Rube, C.3
-
119
-
-
0037479926
-
Erythropoietin regulates tumour growth of human malignancies
-
Yasuda Y, Fujita Y, Matsuo T, et al. Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 2003; 24: 1021.
-
(2003)
Carcinogenesis
, vol.24
, pp. 1021
-
-
Yasuda, Y.1
Fujita, Y.2
Matsuo, T.3
-
120
-
-
0027049472
-
The molecular mechanism of erythropoietin action
-
Koury MJ, Bondurant MC. The molecular mechanism of erythropoietin action. Eur J Biochem 1992; 210: 649.
-
(1992)
Eur J Biochem
, vol.210
, pp. 649
-
-
Koury, M.J.1
Bondurant, M.C.2
-
121
-
-
0032076542
-
Jak2 is essential for signaling through a variety of cytokine receptors
-
Parganas E, Wang D, Stravopodis D, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998; 93: 385.
-
(1998)
Cell
, vol.93
, pp. 385
-
-
Parganas, E.1
Wang, D.2
Stravopodis, D.3
-
122
-
-
0036384462
-
Erythropoietin and VEGF exhibit equal angiogenic potential
-
Jaquet K, Krause K, Tawakol-Khodai M, Geidel S, Kuck KH. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 2002; 64: 326.
-
(2002)
Microvasc Res
, vol.64
, pp. 326
-
-
Jaquet, K.1
Krause, K.2
Tawakol-Khodai, M.3
Geidel, S.4
Kuck, K.H.5
-
123
-
-
0004088968
-
-
Fourth edition, McGraw-Hill, Toronto
-
Tannock IF, Hill RP, Bristow RG, Harrington L. The basic science of oncology. Fourth edition, McGraw-Hill, Toronto 2005.
-
(2005)
The basic science of oncology
-
-
Tannock, I.F.1
Hill, R.P.2
Bristow, R.G.3
Harrington, L.4
-
124
-
-
0021239128
-
The Medical Research Council trial of misonidazole in carcinoma of the uterine cervix. A report from the MRC Working Party on misonidazole for cancer of the cervix
-
Dische S. The Medical Research Council trial of misonidazole in carcinoma of the uterine cervix. A report from the MRC Working Party on misonidazole for cancer of the cervix. Br J Radiol 1984; 57: 491.
-
(1984)
Br J Radiol
, vol.57
, pp. 491
-
-
Dische, S.1
-
125
-
-
0027408134
-
A trial of Ro 03-8799 (pimonidazole) in carcinoma of the uterine cervix: An interim report from the Medical Research Council Working Party on advanced carcinoma of the cervix
-
Dische S. A trial of Ro 03-8799 (pimonidazole) in carcinoma of the uterine cervix: an interim report from the Medical Research Council Working Party on advanced carcinoma of the cervix. Radiother Oncol 1993; 26: 93.
-
(1993)
Radiother Oncol
, vol.26
, pp. 93
-
-
Dische, S.1
-
126
-
-
0024407376
-
Misonidazole combined with radiotherapy in the treatment of carcinoma of the uterine cervix
-
Overgaard J, Bentzen SM, Kolstad P, et al. Misonidazole combined with radiotherapy in the treatment of carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1989; 16: 1069.
-
(1989)
Int J Radiat Oncol Biol Phys
, vol.16
, pp. 1069
-
-
Overgaard, J.1
Bentzen, S.M.2
Kolstad, P.3
-
127
-
-
0029935945
-
A randomised study of ornidazole as a radiosensitiser in carcinoma of the cervix: Long term results
-
Okkan S, Atkovar G, Sahinler I, Turkan S, Uzel R. A randomised study of ornidazole as a radiosensitiser in carcinoma of the cervix: long term results. Br J Cancer Suppl 1996; 27: S282.
-
(1996)
Br J Cancer Suppl
, vol.27
-
-
Okkan, S.1
Atkovar, G.2
Sahinler, I.3
Turkan, S.4
Uzel, R.5
-
128
-
-
0032995268
-
Irradiation with or without misonidazole for patients with stages IIIB and IVA carcinoma of the cervix: Final results of RTOG 80-05. Radiation Therapy Oncology Group
-
Grigsby PW, Winter K, Wasserman TM, et al. Irradiation with or without misonidazole for patients with stages IIIB and IVA carcinoma of the cervix: final results of RTOG 80-05. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1999; 44: 513.
-
(1999)
Int J Radiat Oncol Biol Phys
, vol.44
, pp. 513
-
-
Grigsby, P.W.1
Winter, K.2
Wasserman, T.M.3
-
129
-
-
1942439101
-
A phase III randomized study of misonidazole plus radiation vs. radiation alone for cervix cancer
-
Chan P, Milosevic M, Fyles A, et al. A phase III randomized study of misonidazole plus radiation vs. radiation alone for cervix cancer. Radiother Oncol 2004; 70: 295.
-
(2004)
Radiother Oncol
, vol.70
, pp. 295
-
-
Chan, P.1
Milosevic, M.2
Fyles, A.3
-
130
-
-
33846224376
-
AK-2123 (Sanazol) as a radiation sensitizer in the treatment of stage III cervical cancer: Results of an IAEA multicentre randomised trial
-
Dobrowsky W, Huigol NG, Jayatilake RS, et al. AK-2123 (Sanazol) as a radiation sensitizer in the treatment of stage III cervical cancer: results of an IAEA multicentre randomised trial. Radiother Oncol 2007; 82: 24.
-
(2007)
Radiother Oncol
, vol.82
, pp. 24
-
-
Dobrowsky, W.1
Huigol, N.G.2
Jayatilake, R.S.3
-
131
-
-
24344486882
-
Local tumour control in women with carcinoma of the cervix treated with the addition of nitroimidazole agents to radiotherapy: A meta-analysis
-
Dayes IS, Abuzallouf S. Local tumour control in women with carcinoma of the cervix treated with the addition of nitroimidazole agents to radiotherapy: a meta-analysis. Br J Radiol 2005; 78: 777.
-
(2005)
Br J Radiol
, vol.78
, pp. 777
-
-
Dayes, I.S.1
Abuzallouf, S.2
-
132
-
-
0028632781
-
Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors
-
Overgaard J. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res 1994; 6: 509.
-
(1994)
Oncol Res
, vol.6
, pp. 509
-
-
Overgaard, J.1
-
133
-
-
0037376123
-
Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: A randomized trial
-
Lorvidhaya V, Chitapanarux I, Sangruchi S, et al. Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial, Int J Radiat Oncol Biol Phys 2003; 55: 1226.
-
(2003)
Int J Radiat Oncol Biol Phys
, vol.55
, pp. 1226
-
-
Lorvidhaya, V.1
Chitapanarux, I.2
Sangruchi, S.3
-
134
-
-
0033852149
-
Interim results of a randomized trial of mitomycin C as an adjunct to radical radiotherapy in the treatment of locally advanced squamous-cell carcinoma of the cervix
-
Roberts KB, Urdaneta N, Vera R, et al. Interim results of a randomized trial of mitomycin C as an adjunct to radical radiotherapy in the treatment of locally advanced squamous-cell carcinoma of the cervix. Int J Cancer 2000; 90: 206.
-
(2000)
Int J Cancer
, vol.90
, pp. 206
-
-
Roberts, K.B.1
Urdaneta, N.2
Vera, R.3
-
135
-
-
0030804916
-
Role of mitomycin C in the development of late bowel toxicity following chemoradiation for locally advanced carcinoma of the cervix
-
Rakovitch E, Fyles AW, Pintilie M, Leung PM. Role of mitomycin C in the development of late bowel toxicity following chemoradiation for locally advanced carcinoma of the cervix. Int J Radiat Oncol Biol Phys 1997; 38: 979.
-
(1997)
Int J Radiat Oncol Biol Phys
, vol.38
, pp. 979
-
-
Rakovitch, E.1
Fyles, A.W.2
Pintilie, M.3
Leung, P.M.4
-
136
-
-
0027288316
-
4233 (tirapazamine): A new anticancer drug exploiting hypoxia in solid tumours
-
Brown JM. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer 1993; 67: 1163.
-
(1993)
Br J Cancer
, vol.67
, pp. 1163
-
-
Brown, J.S.1
-
137
-
-
0034306888
-
A phase I/II evaluation of tirapazamine administered intravenously concurrent with cisplatin and radiotherapy in women with locally advanced cervical cancer
-
Craighead PS, Pearcey R, Stuart G. A phase I/II evaluation of tirapazamine administered intravenously concurrent with cisplatin and radiotherapy in women with locally advanced cervical cancer. Int J Radiat Oncol Biol Phys 2000; 48: 791.
-
(2000)
Int J Radiat Oncol Biol Phys
, vol.48
, pp. 791
-
-
Craighead, P.S.1
Pearcey, R.2
Stuart, G.3
-
138
-
-
55849124908
-
A phase I study of tirapazamine in combination with radiation and weekly cisplatin in patients with locally advanced cervical cancer
-
Rischin DN, Narayan K, Oza, A, et al. A phase I study of tirapazamine in combination with radiation and weekly cisplatin in patients with locally advanced cervical cancer. Proc Am Soc Clin Oncol Part I 2001; 25: 5543.
-
(2001)
Proc Am Soc Clin Oncol Part
, vol.1
, Issue.25
, pp. 5543
-
-
Rischin, D.N.1
Narayan, K.2
Oza, A.3
-
139
-
-
22944491515
-
Clinical potential of inhibitors of survival pathways and activators of apoptotic pathways in treatment of cervical cancer: Changing the apoptotic balance
-
Hougardy BM, Maduro JH, van der Zee AG, et al. Clinical potential of inhibitors of survival pathways and activators of apoptotic pathways in treatment of cervical cancer: changing the apoptotic balance. Lancet Oncol 2005; 6: 589.
-
(2005)
Lancet Oncol
, vol.6
, pp. 589
-
-
Hougardy, B.M.1
Maduro, J.H.2
van der Zee, A.G.3
-
140
-
-
0030996297
-
The receptor for the cytotoxic ligand TRAIL
-
Pan G, O'Rourke K, Chinnaiyan AM, et al. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276: 111.
-
(1997)
Science
, vol.276
, pp. 111
-
-
Pan, G.1
O'Rourke, K.2
Chinnaiyan, A.M.3
-
141
-
-
0030762815
-
An antagonist decoy receptor and a death domain-containing receptor for TRAIL
-
Pan G, Ni J, Wei YF, et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997; 277: 815.
-
(1997)
Science
, vol.277
, pp. 815
-
-
Pan, G.1
Ni, J.2
Wei, Y.F.3
-
142
-
-
17844379782
-
TRAIL is a key target in S-phase slowing-dependent apoptosis induced by interferon-beta in cervical carcinoma cells
-
Vannucchi S, Chiantore MV, Fiorucci G, et al. TRAIL is a key target in S-phase slowing-dependent apoptosis induced by interferon-beta in cervical carcinoma cells. Oncogene 2005; 24: 2536.
-
(2005)
Oncogene
, vol.24
, pp. 2536
-
-
Vannucchi, S.1
Chiantore, M.V.2
Fiorucci, G.3
-
143
-
-
34248162523
-
Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival
-
Behbakht K, Qamar L, Aldridge CS, et al. Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival. Cancer Res 2007; 67: 3036.
-
(2007)
Cancer Res
, vol.67
, pp. 3036
-
-
Behbakht, K.1
Qamar, L.2
Aldridge, C.S.3
-
144
-
-
32444446274
-
Functional expression of TRAIL receptors TRAIL-R1 and TRAIL-R2 in esophageal adenocarcinoma
-
Younes M, Georgakis GV, Rahmani M, Beer D, Younes A. Functional expression of TRAIL receptors TRAIL-R1 and TRAIL-R2 in esophageal adenocarcinoma. Eur J Cancer 2006; 42: 542.
-
(2006)
Eur J Cancer
, vol.42
, pp. 542
-
-
Younes, M.1
Georgakis, G.V.2
Rahmani, M.3
Beer, D.4
Younes, A.5
-
145
-
-
33846250902
-
TRAIL-R2 mAb, a human agonistic monoclonal antibody to tumor necrosis factor-related apoptosis inducing ligand receptor 2, induces apoptosis in human tumor cells
-
Alderson B, Birse C, Connolly K. TRAIL-R2 mAb, a human agonistic monoclonal antibody to tumor necrosis factor-related apoptosis inducing ligand receptor 2, induces apoptosis in human tumor cells. Proc Am Assoc Cancer Res 2003; 123.
-
(2003)
Proc Am Assoc Cancer Res
, pp. 123
-
-
Alderson, B.1
Birse, C.2
Connolly, K.3
-
146
-
-
34248187996
-
Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1
-
Tolcher AW, Mita M, Meropol NJ, et al. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol 2007; 25: 1390.
-
(2007)
J Clin Oncol
, vol.25
, pp. 1390
-
-
Tolcher, A.W.1
Mita, M.2
Meropol, N.J.3
-
147
-
-
33847167668
-
A phase I safety and pharmacokinetic (PK) study of recombinant APO2L/TRAIL, an apoptosis protein in patients with advanced cancer
-
Herbst R, Mendolson D, Ebbinghaus S, et al. A phase I safety and pharmacokinetic (PK) study of recombinant APO2L/TRAIL, an apoptosis protein in patients with advanced cancer. In: ASCO, J Clin Oncol 2006; 3013.
-
(2006)
ASCO, J Clin Oncol
, pp. 3013
-
-
Herbst, R.1
Mendolson, D.2
Ebbinghaus, S.3
-
148
-
-
55849148234
-
-
Ling J, Herbst R, Mendelson D, et al. Apo2L/TRAIL pharmacokinetics in a phase 1a trial in advanced cancer and lymphoma. In: ASCO Annual Meeting Proceedings. J Clin Oncol (Meeting Abstracts) 2006; 3047.
-
Ling J, Herbst R, Mendelson D, et al. Apo2L/TRAIL pharmacokinetics in a phase 1a trial in advanced cancer and lymphoma. In: ASCO Annual Meeting Proceedings. J Clin Oncol (Meeting Abstracts) 2006; 3047.
-
-
-
-
149
-
-
33644515676
-
Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model
-
Straughn JM Jr., Oliver PG, Zhou T, et al. Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model. Gynecol Oncol 2006; 101: 46.
-
(2006)
Gynecol Oncol
, vol.101
, pp. 46
-
-
Straughn Jr., J.M.1
Oliver, P.G.2
Zhou, T.3
-
150
-
-
33747829837
-
Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: Enhanced effects in vitro and dose-dependent growth delay in vivo
-
Marini P, Denzinger S, Schiller D, et al. Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo. Oncogene 2006; 25: 5145.
-
(2006)
Oncogene
, vol.25
, pp. 5145
-
-
Marini, P.1
Denzinger, S.2
Schiller, D.3
-
151
-
-
0035341494
-
Enhancement of radiosensitivity by proteasome inhibition: Implications for a role of NF-kappaB
-
Russo SM, Tepper JE, Baldwin AS Jr., et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys 2001; 50: 183.
-
(2001)
Int J Radiat Oncol Biol Phys
, vol.50
, pp. 183
-
-
Russo, S.M.1
Tepper, J.E.2
Baldwin Jr., A.S.3
-
152
-
-
0037342894
-
The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents
-
Ma MH, Yang HH, Parker K, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003; 9: 1136.
-
(2003)
Clin Cancer Res
, vol.9
, pp. 1136
-
-
Ma, M.H.1
Yang, H.H.2
Parker, K.3
-
153
-
-
33847751015
-
Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors
-
Birle DC, Hedley DW. Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors. Cancer Res 2007; 67: 1735.
-
(2007)
Cancer Res
, vol.67
, pp. 1735
-
-
Birle, D.C.1
Hedley, D.W.2
-
154
-
-
0037018270
-
Antiviral agent Cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers
-
Abdulkarim B, Sabri S, Deutsch E, et al. Antiviral agent Cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers. Oncogcne 2002; 21: 2334.
-
(2002)
Oncogcne
, vol.21
, pp. 2334
-
-
Abdulkarim, B.1
Sabri, S.2
Deutsch, E.3
-
155
-
-
15244363807
-
Antiviral activity of Cidofovir on a naturally human papillomavirus-16 infected squamous cell carcinoma of the head and neck (SCCHN) cell line improves radiation sensitivity
-
Sirianni N, Wang J, Ferris RL. Antiviral activity of Cidofovir on a naturally human papillomavirus-16 infected squamous cell carcinoma of the head and neck (SCCHN) cell line improves radiation sensitivity. Oral Oncol 2005; 41: 423.
-
(2005)
Oral Oncol
, vol.41
, pp. 423
-
-
Sirianni, N.1
Wang, J.2
Ferris, R.L.3
-
156
-
-
33749170109
-
Cidofovir administered with radiation displays an antiangiogenic effect mediated by E6 inhibition and subsequent TP53-dependent VEGF repression in HPV18+ cell lines
-
Amine A, Vozenin-Brotons MC, Abdulkarim B, et al. Cidofovir administered with radiation displays an antiangiogenic effect mediated by E6 inhibition and subsequent TP53-dependent VEGF repression in HPV18+ cell lines. Radiat Res 2006; 166: 600.
-
(2006)
Radiat Res
, vol.166
, pp. 600
-
-
Amine, A.1
Vozenin-Brotons, M.C.2
Abdulkarim, B.3
-
157
-
-
24944520308
-
HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo
-
Gupta AK, Cerniglia GJ, Mick R, McKenna WG, Muschel RJ. HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. Cancer Res 2005; 65: 8256.
-
(2005)
Cancer Res
, vol.65
, pp. 8256
-
-
Gupta, A.K.1
Cerniglia, G.J.2
Mick, R.3
McKenna, W.G.4
Muschel, R.J.5
-
158
-
-
33749472340
-
Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: Implications for radiotherapy
-
Pore N, Gupta AK, Cerniglia GJ, et al. Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: implications for radiotherapy. Cancer Res 2006; 66: 9252.
-
(2006)
Cancer Res
, vol.66
, pp. 9252
-
-
Pore, N.1
Gupta, A.K.2
Cerniglia, G.J.3
|